118 related articles for article (PubMed ID: 8133104)
1. Interferon (IFN)-alpha 2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN-alpha 2a therapy.
Crowe JS; Gewert DR; Barber KA; Lewis AP; Sims MJ; Davies SL; Salom CL; Wood J; Thomas HC; Thursz M
J Infect Dis; 1994 Apr; 169(4):875-8. PubMed ID: 8133104
[TBL] [Abstract][Full Text] [Related]
2. The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a.
Hosoi H; Imai M; Yamanaka M
J Gastroenterol Hepatol; 1992; 7(4):411-6. PubMed ID: 1515568
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
[TBL] [Abstract][Full Text] [Related]
4. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection.
Lok AS; Lai CL; Leung EK
Hepatology; 1990 Dec; 12(6):1266-70. PubMed ID: 2258142
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody:comparable antiviral effects on wild-type virus and precore mutant.
Aikawa T; Kanai K; Kako M; Kawasaki T; Hino K; Iwabuchi S; Tsubouchi H; Takehira Y; Tsuda F; Okamoto H
J Viral Hepat; 1995; 2(5):243-50. PubMed ID: 8745316
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
Antonelli G; Currenti M; Turriziani O; Dianzani F
J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
[TBL] [Abstract][Full Text] [Related]
7. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
12. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
13. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C?
Wada M; Kang KB; Kinugasa A; Shintani S; Sawada K; Nishigami T; Shimoyama T
Intern Med; 1997 Apr; 36(4):248-54. PubMed ID: 9187562
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
[TBL] [Abstract][Full Text] [Related]
15. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
[TBL] [Abstract][Full Text] [Related]
16. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
17. Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan.
Hou C; Chuang WL; Yu ML; Dai CY; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY
Scand J Gastroenterol; 2000 Dec; 35(12):1288-93. PubMed ID: 11199369
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
19. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver.
Fukuda R; Ishimura N; Hamamoto S; Moritani M; Uchida Y; Ishihara S; Akagi S; Watanabe M; Kinoshita Y
J Med Virol; 2001 Mar; 63(3):220-7. PubMed ID: 11170061
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
